All Outputs (15)

Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study (2020)
Journal Article
Ekström, M., Bornefalk, H., Sköld, C. M., Janson, C., Blomberg, A., Sandberg, J., Bornefalk-Hermansson, A., Currow, D. C., Johnson, M. J., & Sundh, J. (2021). Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study. European respiratory journal, 57(3), https://doi.org/10.1183/13993003.02823-2020

Chronic breathlessness is a dominating symptom that restricts daily life for many people with cardiorespiratory disease [1]. Different dimensions of the symptom, such as the intensity, sensory qualities (SQs) and emotional responses, can be assessed... Read More about Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study.

Prevalence and risk factors of breathlessness across Canada: A national retrospective cohort study in home care and nursing home populations (2020)
Journal Article
Seow, H., Dutta, P., Johnson, M. J., McMillan, K., Guthrie, D. M., Costa, A., & Currow, D. C. (in press). Prevalence and risk factors of breathlessness across Canada: A national retrospective cohort study in home care and nursing home populations. Journal of pain and symptom management, https://doi.org/10.1016/j.jpainsymman.2020.11.034

© 2020 American Academy of Hospice and Palliative Medicine Context: Breathlessness is a symptom associated with poor clinical outcomes and prognosis. Little is known about its long-term trends and associations with social factors including decline in... Read More about Prevalence and risk factors of breathlessness across Canada: A national retrospective cohort study in home care and nursing home populations.

Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release (2020)
Journal Article
Currow, D. C., Kochovska, S., Ferreira, D., & Johnson, M. (2020). Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release. Current opinion in supportive and palliative care, 14(3), 177-181. https://doi.org/10.1097/SPC.0000000000000520

Purpose of Review:
Clinicians who seek to reduce the symptomatic burden of chronic breathlessness by initiating regular low dose morphine have the choice of immediate or sustained release formulations - which will be better for this often frail popu... Read More about Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release.

Activities forgone because of chronic breathlessness: a cross-sectional, population prevalence study (2020)
Journal Article
Kochovska, S., Chang, S., Morgan, D. D., Ferreira, D., Sidhu, M., Saleh Moussa, R., Johnson, M. J., Ekström, M., & Currow, D. C. (2020). Activities forgone because of chronic breathlessness: a cross-sectional, population prevalence study. Palliative Medicine Reports, 1(1), 166-170. https://doi.org/10.1089/pmr.2020.0083

Background
Chronic breathlessness is a prevalent, disabling syndrome affecting many people for years. Identifying the impact of chronic breathlessness on people’s activities in the general population is pivotal for designing symptom management strat... Read More about Activities forgone because of chronic breathlessness: a cross-sectional, population prevalence study.

Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness (2020)
Journal Article
Ekström, M., Johnson, M. J., Huang, C., & Currow, D. C. (2020). Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness. European respiratory journal, 56(2), Article 1902202. https://doi.org/10.1183/13993003.02202-2019

Copyright ©ERS 2020. BACKGROUND: Chronic breathlessness has devastating consequences. The minimal clinically important difference (MCID) for current intensity has been estimated as 9 mm on a 100-mm visual analogue scale (VAS). We aimed to determine M... Read More about Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness.

A systematic review and meta-analysis of studies comparing burden from lung cancer and chronic obstructive pulmonary disease (2020)
Journal Article
Luckett, T., San Martin, A., Currow, D. C., Johnson, M. J., Barnes-Harris, M. M. M., & Phillips, J. L. (2020). A systematic review and meta-analysis of studies comparing burden from lung cancer and chronic obstructive pulmonary disease. Palliative medicine, 34(10), 1291-1304. https://doi.org/10.1177/0269216320940153

Background: Chronic obstructive pulmonary disease and lung cancer are both life-limiting diseases that confer burden in the form of symptoms and affect functioning and quality of life. Comparing burden between these diseases is of interest to determi... Read More about A systematic review and meta-analysis of studies comparing burden from lung cancer and chronic obstructive pulmonary disease.

COVID-19: guidance on palliative care from a European Respiratory Society international task force (2020)
Journal Article
Janssen, D. J., Maddocks, M., Janssen, D. J. A., Ekström, M., Currow, D. C., Johnson, M. J., Maddocks, M., Simonds, A. K., Tonia, T., & Marsaa, K. (2020). COVID-19: guidance on palliative care from a European Respiratory Society international task force. European respiratory journal, 56(3), 2002583. https://doi.org/10.1183/13993003.02583-2020

Copyright ©ERS 2020. BACKGROUND: Many people are dying from coronavirus disease 2019 (COVID-19), but consensus guidance on palliative care in COVID-19 is lacking. This new life-threatening disease has put healthcare systems under pressure, with the i... Read More about COVID-19: guidance on palliative care from a European Respiratory Society international task force.

Opioids for breathlessness: a narrative review (2020)
Journal Article
Currow, D. C., Johnson, M. J., Pollack, A., Ferreira, D. H., Kochovska, S., Ekström, M., & Harrison, C. (2020). Opioids for breathlessness: a narrative review. BMJ Supportive & Palliative Care, 10(3), 287-295. https://doi.org/10.1136/bmjspcare-2020-002314

ABSTRACT
Chronic breathlessness is a disabling and distressing condition for which there is a growing evidence base for a range of interventions. Non-pharmacological interventions are the mainstay of management and should be optimised prior to use... Read More about Opioids for breathlessness: a narrative review.

Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study (2020)
Journal Article
Baddeley, E., Bravington, A., Johnson, M., Currow, D., Murtagh, F. E., Boland, E., Obita, G., Nelson, A., Seddon, K., Oliver, A., Noble, S., & Boland, J. (2020). Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study. BMJ open, 10(6), Article 039154. https://doi.org/10.1136/bmjopen-2020-039154

INTRODUCTION: Studies regarding the management of malignant bowel obstruction (MBO) report conflicting findings. This is partly due to different outcome measures being used to evaluate severity of MBO and the response to treatments. Furthermore, curr... Read More about Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study.

Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018 (2020)
Journal Article
Clark, J. D., Johnson, M., Fabowale, B., Farrelly, M., & Currow, D. (in press). Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018. Journal of Global Health Reports, 4, Article e2020042

Background
The International Narcotics Control Board (INCB) has overseen international drug control since 1968 with the dual remit of restricting illicit production and use of controlled substances, whilst enabling access for clinical purposes. Two... Read More about Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018.

Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people. (2020)
Journal Article
Currow, D. C., Chang, S., Grande, E. D., Ferreira, D. H., Kochovska, S., Kinchin PhD, I., Johnson, M. J., & Ekstrom, M. (2020). Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people. Journal of pain and symptom management, https://doi.org/10.1016/j.jpainsymman.2020.05.015

Introduction
Chronic breathlessness is associated with poorer quality of life. This population study aimed to define dimensions of quality of life (QoL), and duration and dominant causes of breathlessness that most diminished QoL.

Methods
This... Read More about Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people..

Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study (2020)
Journal Article
Currow, D. C., Johnson, M. J., Pollack, A., Ferreira, D. H., Kochovska, S., Ekström, M., & Harrison, C. (2020). Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study. ERJ Open Research, 6(2), Article 00299-2019. https://doi.org/10.1183/23120541.00299-2019

Chronic breathlessness is a disabling syndrome, prevalent in people with advanced chronic obstructive pulmonary disease (COPD). Regular, low-dose, oral sustained-release morphine is approved in Australia to reduce symptomatic chronic breathlessness.... Read More about Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study.

A Dyadic Growth Modeling Approach for Examining Associations Between Weight Gain and Lung Function Decline (2020)
Journal Article
Cornelius, T., Schwartz, J. E., Balte, P., Bhatt, S. P., Cassano, P. A., Currow, D., Jacobs, D. R., Johnson, M., Kalhan, R., Kronmal, R., Loehr, L., O’Connor, G. T., Smith, B., White, W. B., Yende, S., & Oelsner, E. C. (2020). A Dyadic Growth Modeling Approach for Examining Associations Between Weight Gain and Lung Function Decline. American Journal of Epidemiology, 189(10), 1173-1184. https://doi.org/10.1093/aje/kwaa059

The relationship between body weight and lung function is complex. Using a dyadic multilevel linear modeling approach, treating body mass index (BMI; weight (kg)/height (m)2) and lung function as paired, within-person outcomes, we tested the hypothes... Read More about A Dyadic Growth Modeling Approach for Examining Associations Between Weight Gain and Lung Function Decline.

Managing the supportive care needs of those affected by COVID-19 (2020)
Journal Article
Bajwah, S., Wilcock, A., Towers, R., Costantini, M., Bausewein, C., Johnson, M. J., Simon, S. T., Bendstrup, E., Prentice, W., Johnson, M. J., Currow, D. C., Kreuter, M., Wells, A. U., Birring, S. S., Edmonds, P., & Higginson, I. J. (2020). Managing the supportive care needs of those affected by COVID-19. European respiratory journal, 55(4), Article 2000815. https://doi.org/10.1183/13993003.00815-2020

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M. J., Bajwah, S., Lovell, N., Yi, D., Hart, S., Crosby, V., Poad, H., Currow, D., Best, E., & Brown, S. (2020). Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 75(2), 176-179. https://doi.org/10.1136/thoraxjnl-2019-213879

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with... Read More about Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).